Granulovacuolar Degeneration in Hippocampus of Neurodegenerative Diseases: Quantitative Study

Maher Kurdi,1,2 Esther Chin,1 and Lee Cyn Ang3

1Department of Pathology, London Health Science Centre, Western University, London, ON, Canada N6A 5C1
2Department of Pathology, King Abdul-Aziz University, Jeddah, Saudi Arabia
3Department of Pathology, Schulich School of Medicine & Dentistry, Western University, London, ON, Canada N6A 5C1

Correspondence should be addressed to Maher Kurdi; drc_marmar@hotmail.com

Received 11 July 2016; Revised 15 September 2016; Accepted 29 September 2016

Academic Editor: Seishi Terada

Copyright © 2016 Maher Kurdi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Granulovacuolar degeneration (GVD) is one of the pathological features long associated with Alzheimer’s disease (AD) and normal aging. Aim. We investigate the frequency of GVDs in AD, other neurodegenerative diseases, and normal aging, with attempt to determine whether the GVD has preponderance in any particular neurodegenerative disease other than AD. Materials and Methods. A retrospective review of 111 autopsied cases with a variety of neurodegenerative diseases and 70 control cases without pathological evidence of neurodegeneration was evaluated quantitatively. The microscopic examination was applied on coronal sections of hippocampi using Hematoxylin and Eosin (H&E) and Bielschowsky silver impregnation. The mean percentage of neurons with GVDs was calculated through all sectors of Ammon’s horn for each case. Result. We found that neurons with GVD, in cases with or without neurodegenerative diseases, were found predominantly in CA1 and CA2 sectors of hippocampus. The GVD count in AD was significantly increased in CA1 and CA2 compared to other neurodegenerative cases as well as normal aging controls. In AD/LBD there was a significant increase in GVD in CA1 whereas in LBD there was no significant change in GVD. Conclusions. The frequency of GVD in AD is due to the disease process and attributes the increase for AD/LBD to the AD component.

1. Introduction

GVD was first reported by Simchowicz in the hippocampus in cases of senile dementia in 1911 [1] and its ultrastructural characteristics were subsequently described by Hirano et al. in 1968 [2]. Microscopically, it is depicted by intraneuronal accumulation of large membrane-bound vacuoles harboring argyrophilic granules [3]. Ultrastructurally, the cytoplasmic vacuoles are 3–5 μm in diameter, each containing a single granule measuring 0.5–1.5 μm wide [4]. These granules contain epitopes for a group of protein constituents linking GVD with neurodegenerative processes. The protein constituents described in GVD, such as neurofilament protein, phosphorylated tau, ubiquitin, tropomyosin, vimentin, and, interestingly, mitotic proteins, are also represented in the autophagic ubiquitin proteasome system [5]. Therefore, GVD is postulated to be derived from cellular autophagic processes and appears when phosphorylated tau begins to aggregate into neurofibrillary tangles [6]. Nevertheless, GVD was not considered to be directly involved in neurofibrillary tangle (NFT) formation or Aβ plaque deposition [2]. Studies have examined the prevalence and distribution of GVD in human postmortem brains [7] as well as rat brains [8]. Tomlinson and Kitchener [9] have measured the degree of GVD in both normal aging population and demented patients. Generally, pyramidal neurons in the subiculum and CA1 zone of the hippocampus are most susceptible to the GVD [10]. Ventrolateral quadrant of the hippocampus is more vulnerable to GVD than the rest of the hippocampus while parahippocampal cortex is much less vulnerable [11]. Neurons in CA2, CA3, CA4, and subiculum are less frequently affected by GVD [12]. Rare GVDs were described in neocortex, hypothalamus, amygdala, and the paramedian nuclei of the midbrain [13]. The present study attempts to establish statistically
the significance of GVD in the hippocampus in different neurodegenerative diseases (including AD, LBD, and AD with LBD, AGD, CBD, FTLD-U, MSA, PD, PiD, and PSP) in comparison to normal aging, in order to determine whether the degree of GVD is due to disease or aging process.

2. Materials and Methods

2.1. Specimens. We retrospectively examined 181 postmortem brains with ages ranging from 43 to 95 years in the period between 1993 and 2005 at the University Hospital (London Health Sciences Center), London, Ontario, Canada. Of these, 70 were control cases with no evidence of clinical dementia or movement disorders, and disclosed only age-related changes without neurodegenerative findings on neuropathological examination. The brains of neurodegenerative cases (\(n = 111\)) were examined as well. These included 56 AD, 9 AD/LBD, 2 AGD, 4 CBD, 10 FTLD-U, 10 LBD, 5 MSA, 3 PD, 2 PiD, and 10 PSP. These cases showed clinically progressive dementia or movement disorders and exhibited definite neuropathological findings of the respective diseases as determined by our neuropathologists. Immunohistochemistry for tau (PHF), alpha-synuclein, beta-amyloid, and ubiquitin has been applied on sections of the neurodegenerative diseases and when necessary to the control cases. The Bielschowsky silver impregnation is performed on all hippocampal sections and frontal sections. The AD cases were diagnosed using the NFT staging (Braak and Braak) and plaque score (CERAD). The pathological diagnosis of AD was based on NFT staging of 4 or above and plaque score of 2 or above. Coronal sections of the hippocampus at the level of lateral geniculate body were taken for examination. We reviewed the age, gender, clinical history, and diagnosis from medical records of all cases. This study has been approved by Research Ethics Board, University of Western Ontario, and LHSC in London, Canada.

2.2. Tissue Preparation and Histochemistry. All specimens were fixed in 20% neutral buffered formalin and embedded in paraffin wax. Sections were stained with both Hematoxylin and Eosin (H&E) and Bielschowsky silver impregnation and examined under light microscopy (Figures 1(a) and 1(b)).

2.3. Quantitative Analysis of GVDs. The area analyzed included all four sectors of hippocampus (Ammon's horn). The total numbers of the neurons and the number of neurons affected by GVD were counted sequentially over the entire area with aid of Bielschowsky stain, using light microscopy at magnification of 250 times. The total average mean value for each disease in each sector was calculated and regarded as a mean percentage of GVD:

\[
\text{Mean Percentage of GVD} = \frac{\text{Number of neurons affected by GVD}}{\text{Total numbers of neurons in the entire area}} \times 100.
\]

Comparison of means between disease groups as well as with the controls and the test significance were determined using two tailed statistical methods, one-way ANOVA and Post Hoc Scheffe test. The proportions were transformed using the arcsin (sqrt) to improve the equity of variances and the normal distribution. The one-way ANOVA is used to compare the effect of the disease on mean percentage of GVDs in each hippocampus. The Post Hoc Scheffe test is used to compare the mean percentage of GVD of disease groups.
Table 1: The table shows the mean age and sex ration for all neurodegenerative and control cases.

| Cases   | n  | Female Mean | SD | %  | Male Mean | SD | %  |
|---------|----|-------------|----|----|-----------|----|----|
| AD      | 56 | 77.75       | 10.78 | 40  | 70.18   | 17 | 29.82 |
| AD/LBD  | 9  | 80.62       | 7.28 | 5   | 55.56   | 4  | 44.44 |
| AGD     | 2  | 82.50       | 4.94 | 0   | 0       | 2  | 100  |
| CBD     | 4  | 75.75       | 6.13 | 2   | 50      | 2  | 50   |
| Control | 70 | 73.57       | 8.19 | 37  | 52.86   | 33 | 47.14 |
| FTLD    | 10 | 72.16       | 13.49 | 4   | 66.67   | 2  | 33.33 |
| LBD     | 10 | 77.40       | 8.32 | 5   | 50      | 5  | 50   |
| MSA     | 5  | 64.20       | 12.27 | 2   | 60      | 3  | 60   |
| PD      | 3  | 75.33       | 5.77 | 1   | 66.67   | 2  | 66.67 |
| PSP     | 10 | 73.66       | 5.60 | 1   | 83.33   | 5  | 83.33 |
| PiD     | 2  | 70.50       | 0.70 | 1   | 50      | 1  | 50   |
| Cases   | 181| 75.32       | 9.54 | 98  | 56.32   | 76 | 43.68 |

3. Results

On nonparametric analysis of our data with respect to age and sex, we found that 37 of controls cases were females (52.9%) while 33 of them were males (47.1%). The cases with neurodegenerative diseases were 61 females (58.7%) and 43 males (41.4%). Overall, there were 98 females (56.3%) and 76 males (41.4%) of both control and neurodegenerative cases.

Statistical analysis for control and neurodegenerative cases for age and sex is summarized in Table 1.

Note. Tables 2, 3, 4(a), and 4(b), and Figure 2 outline the main findings of the following observational and statistical results.

3.1. Observational Results

3.1.1. GVD in Control and Neurodegenerative Patients. Qualitatively, GVD is present in CA1 in all AD, AD/LBD, AGD, CBD, LBD, PSP and PD, taking into account that the number of PD and AGD cases studied is very small (3 and 2 cases, resp.). In the control cases and other neurodegenerative diseases (FTLD, MSA, and PiD), CA1 is the most affected sector by GVD. GVD in CA1 was found in 62 of the 70 control cases. GVD was not found in 8 cases with age below 60 years in CA1 sector. Qualitatively, neurons with GVD in CA1 are apparently found in all normal controls with the age above 60 years. The CA2 is the second most likely affected sector by GVD, followed by CA4 with the least frequency in CA3 (see Table 2).

3.2. Statistical Results. The means and standard deviations for the individuals with neurodegenerative diseases and controls are in Table 3.

3.2.1. GVD at CA1 Sector in Neurodegenerative and Control Cases (Table 4(a)). AD (p < 0.0001) and AD/LBD (p = 0.0118, <0.05) differed significantly in mean percentage of neurons with GVD in CA1 from the normal controls. LBD (without the AD component) shows no significant increase in neurons with GVD from control. Similarly, the other neurodegenerative diseases showed no significant increase in neurons with GVD compared to normal controls. Although
in AGD, CDB, and PSP the means are higher than the normal controls but the differences are not statistically significant. The number of cases for AGD and CBD are small, and therefore the results are not considered meaningful.

The mean GVD counts of AD are also statistically significant higher than FTLD-U, LBD, PSP, and MSA. Applying Dunn's test, the only significant difference occurs between AD and FTLD-U and MSA. Similarly the mean GVD count of AD/LBD is significantly higher than FTLD-U, and MSA and Dunn's test are also significant.

3.2.2. GVD at CA2 Sector in Neurodegenerative and Control Cases (Table 4(b)). In CA2 sector, only AD ($p = 0.0287$, <0.05) and AD/LBD ($p = 0.049$, <0.05) show significant
difference in mean percentage of neurons with GVD from the control. Although, in AGD, CDB, LBD, and PSP, the means are higher than the controls, the differences are not statistically significant. The mean percentage of neurons with GVD is not significantly different in AD compared to any of the other neurodegenerative diseases.

3.2.3. GVD at CA3 Sector in Neurodegenerative and Control Cases. Although the individual mean values of GVD counts for AD, AD/LBD, AGD, CDB, LBD, and PSP are higher than the control, there is no significant difference in mean percentage of neurons with GVD between neurodegenerative diseases (including AD) and control cases. There are also no significant differences in mean percentage of neurons with GVD between AD and any other neurodegenerative diseases.

3.2.4. GVD at CA4 Sector in Neurodegenerative and Control Cases. Although the individual mean values of GVD counts for AD, AD/LBD, AGD, CDB, LBD, PiD, and PSP are higher than the control, only AD (p = 0.0283, <0.05) shows a significant difference in the mean percentage of neurons of GVD compared to control cases. There is no significant difference in mean percentage of neurons with GVD between AD and other neurodegenerative diseases.

4. Discussion

Although GVD of hippocampal pyramidal neurons is usually associated with senile dementia of the Alzheimer's disease, it has been found in normal aging brain [10], as well as brains from patients with PSP, PiD, PD, Guam's Parkinson-ALS-dementia diseases [2], and Down's syndrome [14]. The degree of GVD per neuron is also found to correlate with the severity of dementia [15].

GVD can be detected with routine histological stains such as Hematoxylin and Eosin, silver impregnation techniques (such as Bielschowsky), and other immunohistochemical stains including tau [16], TDP-43 [17], ubiquitin [18], GSK [16], CHMP2B [19], and Casein-kinase 1 (CK-1) [20].

Our data show that GVD can be identified qualitatively in neurons of the hippocampi of patients with the neurodegenerative diseases as well as cognitively normal controls above the age of 60 years. These findings replicated those of Xu et al. [7] who found 54 of 75 nondemented cases above 60 years harboring GVD in CA1 and CA2, while one case from the 21 patients below age of 60 showed GVD. Tomlinson and Kitchener [9] measured the degree of GVD in both mentally normal aging population and dementia patients. In their study, the topographic distribution of GVD within the hippocampus was found to be identical in 30 nondemented elderly people and 25 people with senile dementia. Only two examined cases below age of 50 showed neuronal cells affected with GVD. Is et al. [8] examined 44 experimental rats between age of one month and 24 months and they found that GVD is present in all areas of the hippocampus in rats with increasing the age.

In our study, the quantitative data on the percentages of hippocampal neurons with GVD among neurodegenerative cases and cognitively normal controls can help in distinguishing the neurodegenerative effect from age-related changes. Among the neurodegenerative diseases, only AD and AD/LBD showed statistically significant increase in percentages of neurons with GVD compared with age matched normal controls in CA1 and CA2. Interestingly, LBD without any AD component has no effect on percentages of neurons with GVD in CA1 and CA2. In CA3, there is no significant difference in percentage of neurons with GVD between any neurodegenerative diseases and the aged match controls. In CA4, only AD showed an impact of increasing the percentages of neurons with GVD.

Xu et al. [7] identified GVDs in 43 dementia cases, particularly the AD cases, and they found that the difference between the number of affected neurons with GVD in AD and in non-AD dementia was statistically significant. In their study, they included AD, Pick's disease (PiD), multi-infarct dementia, and atypical dementia (defined as non-Alzheimer's, non-Pick's dementia with Fahr's syndrome), whereas our study is the first to examine quantitatively the presence of hippocampal GVD in AD/LBD, AGD, CDB, LBD, PSP, and PD in addition to AD, PiD, and normal aging.

5. Conclusions

GVD can be identified in nondemented patients linked to aging process or non-Alzheimer's neurodegenerative diseases. The increased frequency of GVD in hippocampus predominantly at the CA1 and CA2 in AD and AD/LBD suggests that the AD disease process does enhance the generation of GVD. Our finding further supports that LBD without the AD component has no effect on the frequency of GVD in the hippocampus. We propose that quantifying GVD in CA1/CA2 on a single standard section of the hippocampus with the Bielschowsky stain could be a useful diagnostic marker for AD, especially in institutions where extensive sampling of brains and the use of a large panel of immunostain are not feasible.

Abbreviations

GVD: Granulovacuolar degeneration
AD: Alzheimer's disease
LBD: Lewy body disease
AGD: Argyrophilic grain disease
CBD: Corticobasal degeneration
FTLD-U: Frontotemporal lobar degeneration
MSA: Multiple system atrophy
PD: Parkinson's disease
PiD: Pick's disease
PSP: Progressive supranuclear palsy
NFT: Neurofibrillary tangle.

Competing Interests

The authors declare that there are no competing interests regarding the publication of this paper.


References

[1] J. Kahn, B. H. Anderton, A. Probst, J. Ulrich, and M. M. Esiri, “Immunohistological study of granulovacuolar degeneration using monoclonal antibodies,” to neurofilaments,” Journal of Neurology, Neurosurgery & Psychiatry, vol. 48, no. 9, pp. 924–926, 1985.

[2] A. Hirano, H. M. Dembitzer, L. T. Kurland, and H. M. Zimmerman, “The fine structure of some intraganglionic alterations: neurofibrillary Tangle, Granulovacuolar Bodies and ‘Rod-Like’ structures as seen in Guam amyotrophic lateral sclerosis and parkinsonism-dementia complex,” Journal of Neuropathology and Experimental Neurology, vol. 27, no. 2, pp. 167–182, 1968.

[3] K. E. Funk, R. E. Mrak, and J. Kuret, “Granulovacuolar degeneration (GVD) bodies of Alzheimer’s disease (AD) resemble late-stage autophagic organelles,” Neuropathology and Applied Neurobiology, vol. 37, no. 3, pp. 340–345, 2011.

[4] K. Okamoto, S. Hirai, Y. Izuka, T. Yamasawa, and M. Watanabe, “Reexamination of granulovacuolar degeneration,” Acta Neuropathologica, vol. 82, no. 5, pp. 340–345, 1991.

[5] R. J. Castellani, Y. Gupta, B. Sheng et al., “A novel origin for granulovacuolar degeneration in aging and Alzheimer’s disease: parallels to stress granules,” Laboratory Investigation, vol. 91, no. 12, pp. 1777–1786, 2011.

[6] C. Stadelmann, T. L. Deckwerth, A. Srinivasan et al., “Activation of caspase-3 in single neurons and autophagic granules of granulovacuolar degeneration in Alzheimer’s disease: evidence for apoptotic cell death,” American Journal of Pathology, vol. 155, no. 5, pp. 1459–1466, 1999.

[7] M. Xu, H. Shibayama, H. Kobayashi et al., “Granulovacuolar degeneration in the hippocampal cortex of aging and demented patients—a quantitative study,” Acta Neuropathologica, vol. 85, no. 1, pp. 1–9, 1992.

[8] M. Is, N. U. Comunoglu, C. Comunoglu, B. Eren, I. D. Ekici, and F. Ozkan, “Age-related changes in the rat hippocampus,” Journal of Clinical Neuroscience, vol. 15, no. 5, pp. 568–574, 2008.

[9] B. E. Tomlinson and D. Kitchener, “Granulovacuolar degeneration of hippocampal pyramidal cells,” Journal of Pathology, vol. 106, no. 3, pp. 165–185, 1972.

[10] M. J. Ball and P. Lo, “Granulovacuolar degeneration in the ageing brain and in dementia,” Journal of Neuropathology and Experimental Neurology, vol. 36, no. 3, pp. 474–487, 1977.

[11] J. S. Woodard, “Clinicopathologic significance of granulovacuolar degeneration in Alzheimer’s disease,” Journal of Neuropathology and Experimental Neurology, vol. 21, no. 1, pp. 85–91, 1962.

[12] M. J. Ball, “Topographic distribution of neurofibrillary tangles and granulovacuolar degeneration in hippocampal cortex of aging and demented patients. A quantitative study,” Acta Neuropathologica, vol. 42, no. 2, pp. 73–80, 1978.

[13] J. C. Steele, J. C. Richardson, and J. Olszewski, “Progressive supranuclear palsy: a heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia,” Archives of Neurology, vol. 10, no. 4, pp. 333–339, 1964.

[14] M. J. Ball and K. Nuttal, “Topography of neurofibrillary tangles and granulovacuoles in hippocampi of patients with Down’s syndrome: Quantitative comparison with normal ageing and Alzheimer’s disease,” Neuropathology and Applied Neurobiology, vol. 7, no. 1, pp. 13–20, 1981.

[15] B. E. Tomlinson, G. Blessed, and M. Roth, “Observations on the brains of non-demented old people,” Journal of the Neurological Sciences, vol. 7, no. 2, pp. 331–356, 1968.